Invera Wealth Advisors LLC Has $2.97 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Invera Wealth Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW) by 70.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 31,078 shares of the medical research company’s stock after acquiring an additional 12,809 shares during the quarter. Edwards Lifesciences accounts for 2.5% of Invera Wealth Advisors LLC’s holdings, making the stock its 17th largest position. Invera Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $2,970,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in EW. PFG Investments LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $287,000. Raymond James & Associates raised its stake in shares of Edwards Lifesciences by 8.5% during the first quarter. Raymond James & Associates now owns 1,775,106 shares of the medical research company’s stock valued at $169,629,000 after acquiring an additional 139,515 shares during the last quarter. Accordant Advisory Group Inc acquired a new position in shares of Edwards Lifesciences during the first quarter worth $174,000. New Century Financial Group LLC bought a new stake in shares of Edwards Lifesciences in the first quarter worth $255,000. Finally, Legacy Wealth Asset Management LLC grew its position in shares of Edwards Lifesciences by 2.7% in the 1st quarter. Legacy Wealth Asset Management LLC now owns 17,410 shares of the medical research company’s stock valued at $1,664,000 after buying an additional 452 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.48 during trading on Monday, reaching $85.95. 2,931,204 shares of the company traded hands, compared to its average volume of 3,839,852. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The firm has a 50 day simple moving average of $90.27 and a 200-day simple moving average of $79.06. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The stock has a market capitalization of $51.74 billion, a PE ratio of 37.05, a P/E/G ratio of 4.28 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Evercore ISI cut their price objective on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $92.71.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now directly owns 173,849 shares in the company, valued at approximately $16,049,739.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now directly owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 in the last ninety days. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.